ReviewJournal of skin cancer2014
Risk of second cancers in merkel cell carcinoma: a meta-analysis of population based cohort studies.
Review in Journal of skin cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- How Strong Is the Link Between Merkel Cell Carcinoma and the Occurrence of Other Skin Cancer Types? A Meta-Analysis.Experimental dermatology · 2025Pooled it
- Merkel Cell Carcinoma: Evolving Therapeutics, Continued Challenges.Head & neck · 2025Review
- Coexistence of neuroendocrine carcinoma and squamous cell carcinoma of the skin after kidney transplantation: a case report.Archives of craniofacial surgery · 2025Article
- Development of metastatic Merkel cell carcinoma following the excision of same-sided recurrent auricular melanoma.Clinical case reports · 2022Article
- Clinical Features and Prognosis of Merkel Cell Carcinoma in Elderly Patients.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- A Report of 13 Cases of Merkel Cell Carcinoma: Single-Center Experience and Review of the Literature.Annals of dermatology · 2019Article
- Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.Reviews in endocrine & metabolic disorders · 2017Review
- Iranian university students lifestyle and health status survey: study profile.Journal of diabetes and metabolic disorders · 2017Article
- Malignant melanoma after treatment for Merkel cell carcinoma.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of second cancers in Merkel cell carcinoma (MCC) remains uncertain since risk estimates vary worldwide. The global MCC population is growing and there is a demand for better knowledge of prognosis of this disease. The Cochrane Database of Systematic Reviews, MEDLINE, and EMBASE search engines were searched for the relevant literature between January 1999 and September 2014 by use of explicit search criteria. The main outcome was second malignancies associated with MCC patients measured by standardized incidence ratios (SIRs) or other estimates of risks. Five papers fulfilled the inclusion criteria and reported SIRs of second cancer in MCC which varied from 1.07 to 2.80. Performing meta-analysis using random effects model revealed that there was an increased risk for second malignancies due to MCC (SIR, 1.52; 95% CI, 1.10-2.11). There was a significant increase in risk for malignant melanoma (SIR, 3.09; 95% CI, 2.02-4.73) as compared to all common second malignancies among the studies. Updated knowledge about risk of second malignancies in MCC will help in better assessment of the disease prognosis and will help in optimizing the medical and surgical treatment, radiotherapy, follow-up, and surveillance procedures.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.